In a significant development, Indian pharmaceutical major Glenmark on January 17 2023 announced the launch of the generic version of Novartis’ popular heart failure drug Vymada, which would drastically reduce the price of the live-saving medicine.
Glenmark’s version of a combination of sacubitril and valsartan will be sold under the brand name Sacu VTM. It will be available at Rs 19 per tablet for a dose of 50mg , Rs 35 per tablet for 100mg and Rs 45 per tablet for a dose of 200mg. Novartis sells the 100 mg drug at Rs 85 per tablet, media reports said.
Vymada is said to reduce the risk of cardiovascular related deaths and hospitalizations for patients with chronic heart failure.
IQVIA sales data shows that for the 12 months ending December 2022, the cardiology market is estimated to be Rs 20,730 crore, with an annual growth of 7.7% against the corresponding period last year. The market of sacubitril-valsartan is estimated to be Rs 514 crore with an annual growth of 37.2%.
Vymada’s patent expired this month after which the Delhi high court paved the way for the entry of other pharma majors in this particular drug category.